Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Untch

Showing results (131-140 of 169) with videos related to

Pageof 17
Sort By:
Clinical & Experimental Metastasis|October 17, 2018
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)C Liedtke, Hans-Christian Kolberg, L Kerschke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patientsV Möbus, G von Minckwitz, C Jackisch, et al.
Oncology (Williston Park, N.Y.)|February 3, 2005
Anthracycline and trastuzumab in breast cancer treatmentM Untch, I Himsl, S Kahlert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete responseS Loibl, A Schneeweiss, J Huober, et al.
Clinical Chemistry|November 24, 2001
Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassayP Stieber, R Molina, D W Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)B Gerber, S Loibl, H Eidtmann, et al.
Zentralblatt Fur Gynakologie|September 17, 2002
[Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]G Von Minckwitz, S D Costa, K Brunnert, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trialM Untch, H Eidtmann, A du Bois, et al.
Pageof 17

Showing results (131-140 of 169) with videos related to

Sort By:
Pageof 17
Clinical & Experimental Metastasis|October 17, 2018
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)C Liedtke, Hans-Christian Kolberg, L Kerschke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patientsV Möbus, G von Minckwitz, C Jackisch, et al.
Oncology (Williston Park, N.Y.)|February 3, 2005
Anthracycline and trastuzumab in breast cancer treatmentM Untch, I Himsl, S Kahlert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete responseS Loibl, A Schneeweiss, J Huober, et al.
Clinical Chemistry|November 24, 2001
Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassayP Stieber, R Molina, D W Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)B Gerber, S Loibl, H Eidtmann, et al.
Zentralblatt Fur Gynakologie|September 17, 2002
[Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]G Von Minckwitz, S D Costa, K Brunnert, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trialM Untch, H Eidtmann, A du Bois, et al.
Pageof 17